Core Viewpoint - Fuhong Hanlin (02696) shares rose over 8%, reaching a historical high of 89 HKD, and currently trading at 86.2 HKD with a transaction volume of 73.65 million HKD, following the announcement of the first prescription for its innovative small molecule CDK4/6 inhibitor, Fuzhoning (Citrus Acid Vemurafenib Capsules) [1] Group 1 - Fuhong Hanlin announced that Fuzhoning has been prescribed in over ten hospitals across China, including Fudan University Shanghai Cancer Center and Zhejiang University School of Medicine First Affiliated Hospital [1] - Fuzhoning, in combination with Fulvestrant, is indicated for adult patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) recurrent or metastatic breast cancer who have previously experienced disease progression after endocrine therapy [1] - The drug is owned by Jinjou Aohong Pharmaceutical, a subsidiary of Fosun Pharma (600196), with Fuhong Hanlin responsible for its commercialization in China [1]
复宏汉霖早盘涨超8% 股价再创历史新高 复妥宁全国各地首张处方落地